# A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

> **NCT01059630** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 413 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01059630
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-30
- **Primary completion:** 2014-09-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059630, "A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01059630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*